Latest Development News

Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.

Brookside Energy has established first sales from its Sabres and Whalers wells at the Suttles Pad in Oklahoma, lifting its operated SWISH Play producing well count to 11. Production remains in early flowback, with representative output rates still to come.

Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.

Andromeda Metals has produced 99.9986% purity High Purity Alumina at continuous pilot scale and raised A$3.04 million to advance its next study. But the Great White Project still needs about A$40 million in equity before a final investment decision.

Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.

Veris is using its FY26 results and first-quarter trading update to make the case that its transformation from surveyor to digital and spatial advisory firm is gaining traction. Revenue and underlying EBITDA rose, while the planned Aurecon acquisition adds a near-term test of whether the strategy can convert into stronger earnings.

Boss Energy has maintained FY27 production and cost guidance after a weather-disrupted quarter, while its new wide-spaced wellfield design points to production at Honeymoon through at least FY34. The next test is whether early operating data can validate the study’s assumptions and support a larger regional uranium hub.

Castile Resources has reaffirmed a striking A$1.07 billion pre-tax NPV8 for Rover 1, with bismuth now adding a fifth revenue stream. But the preliminary study still depends on substantial funding, unfinished testwork and a mine plan partly based on Inferred Resources.

Global Gold Mining has reported flotation recoveries of up to 91.4% from laboratory testwork at its Sturec Gold Project in Slovakia, while ongoing drilling supplies data for the project’s pre-feasibility study. The company ended September with $6.134 million in cash after quarterly operating and investing outflows of $1.547 million.

Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.

Alice Queen has reported a 68.0g/t gold interval from its Horn Island drilling, alongside broader high-grade zones inside the existing resource and mineralisation beyond its boundary. Nine assays remain pending, leaving the scale and continuity of the potential extension unresolved.

Nova Minerals has secured the final approvals needed to build and operate its integrated Alaska antimony project, removing a major regulatory hurdle ahead of targeted 2027 production. The US$43.4 million Phase 1 program is funded and equipped, but the company has not yet disclosed production volumes, costs or a detailed construction schedule.